Sulforaphane is a naturally-occurring isothiocyanate with promising chemopreventive 2 activity. An analytical method, utilising LC-MS/MS, that allows the determination of 3 sulforaphane in small volumes of rat plasma following exposure to low dietary doses 4 was developed and validated, and employed to determine its absolute bioavailability 5 and pharmacokinetic characteristics. Rats were treated with either a single intravenous 6 dose of sulforaphane (2.8 μmol/kg) or single oral doses of 2.8, 5.6 and 28 μmol/kg. 7
Introduction 1
Isothiocyanates are promising chemopreventive agents that are present in substantial 2 concentrations in brassica cruciferous vegetables; in epidemiological studies intake of 3 these vegetables was found to afford protection against a number of cancers [1] [2] [3] . 4
Isothiocyanates occur as glucosinolates but are released following exposure to the 5 enzyme myrosinase (β-thioglucoside glucohydrolase) which comes into contact with 6 these compounds during the harvesting, chopping and mastication of these vegetables. 7
Moreover, microbial myrosinase activity in the human intestine contributes to the 8 release of isothiocyanates from their glucosinolate precursors 4 . 9
Epidemiological studies revealed the potential of isothiocyanates to protect 10 against tumourigenesis at a number of sites 5, 6 . Furthermore, studies conducted in 11 animal models established that isothiocyanates can antagonise the carcinogenicity of 12 chemicals, including dietary carcinogens such as polycyclic aromatic hydrocarbons , and at higher doses it also enhances the activity of other 33 deactivating enzyme systems such as glutathione S-transferase 11, 16 . However, 34 4 sulforaphane also acts at the post-initiation stages, for example suppressing the 1 conversion of lung benign tumours to carcinomas in mice 17 . An interesting 2 observation is that mercapturates, the principal metabolites of isothiocyanates, may 3 retain the anticarcinogenic activity of the parent compounds 17, 18 . 4
In the present study an LC-MS/MS method has been developed to determine 5 sulforaphane in rat plasma, and was used to determine the absolute bioavailability of 6 dietary doses of sulforaphane following oral and intravenous administration. Yorkshire, UK). The animals were housed at 22 ± 2 °C, 30-40 % relative humidity in 17 an alternating 12-hr light:dark cycle with light onset at 07.00 hr. The animals were 18 allowed to acclimatise for at least 4 days before commencement of the study; they 19 were then treated, 4 per group, with either a single intravenous dose of sulforaphane 20 (0.5 mg/kg), in a volume of 100 μl of water, or single oral doses of 0.5, 1.0 and 5.0 21 mg/kg, corresponding to 2.8, 5.6 and 28 μmol/kg, dissolved in 1 ml of water. Blood 22 samples (100 μl) were withdrawn from the rat tail at regular time intervals for 8 hours, 23 and placed into lithium-heparinised centrifuge tubes. A sample was also obtained 24 24 hours after administration as well as from untreated rats. 25
26

Sample preparation 27
Aliquots of the plasma (40 μl) were made to 1 ml with 0.01 M phosphate-buffered 28 saline (pH 7.3) and were subsequently extracted with chloroform (5 ml) twice for 30 29 minutes; the layers were separated by centrifugation at 510g for 10 minutes. The 30 combined chloroform extracts were evaporated under nitrogen using an N-EVAP 
Pharmacokinetic analysis 28
Pharmacokinetic analysis was carried out using PK solutions Animal data were analysed individually, and are presented as mean  SD; 8 statistical evaluation was performed using the Student's t-test, where n=4. 9 10
Results
11
A LC-MS/MS method for the measurement of sulforaphane in rat plasma has been 12 developed and validated. No sulforaphane was detected in rat plasma prior to 13 administration of the isothiocyanate. Limit of detection, defined as the lowest 14 concentration of analyte that generates a minimum signal to noise ratio of 3, and limit 15 of quantification, defined as the lowest concentration of analyte that gives rise to an 16 instrument response with a minimum signal to noise ratio of 5, were 5 and 15 ng/ml 17 respectively, following a 20 μl injection (Figures 2A and 2B) . The calibration curve, 18 at a plasma concentration range of 0.01 to 2 μg/ml showed excellent linear 19 relationship, with an R value of 0.99. Recovery of sulforaphane at three plasma 20 concentrations, 0.05, 0.5 and 1.8 μg/ml, was 91, 91 and 88% respectively (n=6). At 21 the same concentrations inter-assay variation was 1.0, 2.2 and 3.2% respectively, 22 whereas intra-assay variation, established at the same concentrations, was 1.5, 6.5 and 23 5% respectively (n=4). Finally, accuracy was established by comparing calculated and 24 theoretical values at two plasma concentrations (0.5 and 1.8 μg/ml); calculated and 25 theoretical values did not differ more than 11 % (n=4). 26 Figure 3 shows the time-course changes in the plasma concentrations of 27 sulforaphane, plotted using a semi logarithmic plot, following intravenous 28 administration to rats; the plasma profile is best described by a two-compartment 29 pharmacokinetic model. Within two hours, plasma concentrations decline to about 30 10% of the levels present 0.5 hour after administration; the concentrations then remain 31 fairly constant indicating a long terminal phase. Similarly, following oral 32 administration of the same dose, a marked and rapid decline in plasma concentrations 33 of sulforaphane is evident between 1 hour after administration, when peak 1 concentrations are achieved, and 2 hours after administration, followed by a 2 prolonged terminal phase (Figure 3) . At the higher doses, however, the decline in 3 plasma concentrations, after maxima have been attained, is more gradual. 4
The pharmacokinetic parameters of sulforaphane following oral and 5 intravenous administration are shown in table 1. The C max and AUC 0-24 values in 6 orally-treated rats increased with dose, but not proportionately; rise in AUC 0-24 and 7
C max values was lower than would be anticipated. Comparison of AUT 0-24 values 8 between the intravenously-and orally-treated groups, at the 0.5 mg/kg dose, indicate 9 an absolute bioavailabilty of 82% which, however, decreased at the higher doses. 10
Finally, the rate of absorption constant k ab , biological half-life t 1/2 and apparent 11 volume of distribution decreased at the highest dose used. Following oral administration, sulforaphane peak plasma concentrations were 29 attained at about one hour, indicating rapid absorption, compatible with its 30 lipophilicity and small molecular size. Similarly, in studies conducted in human 31 volunteers, isothiocyanates, measured as total dithiocarbamates, were rapidly 32 absorbed reaching peak plasma concentrationss one hour after ingestion of broccoli 33 sprout preparations 22 . In a recent study, where sulforaphane levels were determined in 34 8 volunteers consuming a broccoli soup, maxima were attained one hour after intake, in 1 concordance with the present findings in rats 23 . At the highest dose only, the 2 absorption rate constant decreased, and this may explain in part the fact that C max 3 values did not rise proportionately to the dose. This observation raises the possibility 4 that sulforaphane may to some extent be absorbed by a carrier-mediated transport 5 mechanism that is saturated at this dose level. 6
Oral absolute bioavailability of sulforaphane in rats was over 80% at the 7 lowest oral dose studied. It is likely that sulforaphane is subjected to modest first-pass 8 metabolism as glutathione and mercapturate metabolites of this isothiocyanate can be 9 generated by intestinal as well as hepatic enzymes, or even possibly in the blood as it 10 contains low concentrations of glutathione that can interact chemically with the 11 isothiocyanate. Studies using human jejunum in situ have established that 12 sulforaphane is well absorbed by enterocytes where it is conjugated with glutathione 13 during absorption and secreted back into the lumen 24 . 14 In the present study, the oral bioavailability of sulforaphane was dose-15 dependent, being only about 20% at the highest dose studied of 28 μmol/kg, i.e. a 16 quarter of that observed at a dose of 2.8 μmol/kg. These observations imply that 17 intake of sulforaphane supplements may not be as effective as envisaged in achieving 18 high plasma concentrations of the compound. Isothiocyanates display high protein 19 binding 25, 26 , presumably because of their facile interaction with -SH groups, and it is 20 conceivable that at the higher doses protein-binding sites are saturated so that 21 sulforaphane remains free and available for metabolism and excretion. It is relevant to 22 point out that albumin contains only a single residue of free cysteine (Cys34). The 23 observed dose-dependent decrease in biological half-life values concord with such a 24 mechanism of action. Non-linear pharmacokinetics in rats have also been reported for 25 phenethyl isothiocyanate, having an aromatic substituent 25 , and collectively these 26 observations indicate that the isothiocyanate group is more likely to be responsible for 27 this effect rather than the substituent. 28
Following intravenous and oral dosing a rapid marked drop is observed in the 29 plasma concentrations of sulforaphane, and this most likely reflects cellular uptake. 30
Isothiocyanates such as sulforaphane, attain very high intracellular concentrations as a 31 result of their interaction with glutathione 16, 27, 28 . As the absorbed sulforaphane is 32 readily conjugated with glutathione and possibly other thiols, the concentration 33 gradient drives the further cellular uptake of the isothiocyanate, which can achieve9 mM concentrations, and is accompanied by a marked drop in glutathione levels 17 . The 1 glutathione and cysteinylglycine conjugates are exported through membrane 2 transporters such as P-glycoprotein 29, 30 . It has been demonstrated in in vitro studies 3 that peak intracellular concentrations of isothiocyanates are attained within 3 hours of 4 exposure, and intracellular concentration may be as much as 200-fold higher than 5 extracellular concentration 3 . Such extensive intracellular localisation would explain 6 the large apparent volume of distribution. Elimination of sulforaphane was 7 characterised by a long terminal phase; in fact, no major difference was evident in 8 plasma concentrations between 6 and 24 hours following intravenous administration 9 or oral administration at the lower doses. Most likely this is a consequence of protein 10 binding, rendering the isothiocyanate unavailable for elimination through metabolism 11 and excretion. 12
In summary, the present paper demonstrates that in the rat, following oral 13 administration of dietary doses, sulforaphane is rapidly absorbed, achieving high 14 absolute bioavailability at low doses. However, dose-dependent pharmacokinetics 15 was evident, with bioavailability decreasing with increasing dosage. 21   22   23   24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39 
